351 related articles for article (PubMed ID: 22291091)
21. Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein.
Kitagawa K; Oda T; Saito H; Araki A; Gonoi R; Shigemura K; Hashii Y; Katayama T; Fujisawa M; Shirakawa T
Cancer Immunol Immunother; 2017 Jun; 66(6):787-798. PubMed ID: 28299466
[TBL] [Abstract][Full Text] [Related]
22. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.
Walters JN; Ferraro B; Duperret EK; Kraynyak KA; Chu J; Saint-Fleur A; Yan J; Levitsky H; Khan AS; Sardesai NY; Weiner DB
Mol Ther; 2017 Apr; 25(4):976-988. PubMed ID: 28237837
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapeutic targeting of Wilms' tumor protein.
Hutchings Y; Osada T; Woo CY; Clay TM; Lyerly HK; Morse MA
Curr Opin Mol Ther; 2007 Feb; 9(1):62-9. PubMed ID: 17330403
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
25. Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives.
Ogasawara M
Hum Vaccin Immunother; 2024 Dec; 20(1):2296735. PubMed ID: 38148629
[TBL] [Abstract][Full Text] [Related]
26. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
[TBL] [Abstract][Full Text] [Related]
27. [WT1 peptide-based immunotherapy for the treatment of malignancies: focusing on hematological neoplasms].
Oka Y; Tsuboi A; Nishida S; Hosen N; Nakata J; Hashii Y; Maeda T; Oji Y; Kumanogoh A; Sugiyama H
Rinsho Ketsueki; 2011 May; 52(5):235-42. PubMed ID: 21646768
[No Abstract] [Full Text] [Related]
28. Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
Van Genechten T; De Laere M; Van den Bossche J; Stein B; De Rycke K; Deschepper C; Hazes K; Peeters R; Couttenye MM; Van De Walle K; Roelant E; Maes S; Vanden Bossche S; Dekeyzer S; Huizing M; Caluwaert K; Nijs G; Cools N; Verlooy J; Norga K; Verhulst S; Anguille S; Berneman Z; Lion E
BMJ Open; 2024 Mar; 14(3):e077613. PubMed ID: 38503417
[TBL] [Abstract][Full Text] [Related]
29. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
Sugiyama H
Expert Rev Vaccines; 2005 Aug; 4(4):503-12. PubMed ID: 16117707
[TBL] [Abstract][Full Text] [Related]
30. Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.
Coosemans A; Vergote I; Van Gool SW
Expert Rev Clin Immunol; 2014 Jun; 10(6):705-11. PubMed ID: 24784346
[TBL] [Abstract][Full Text] [Related]
31. WT1 Pulsed Human CD141+ Dendritic Cell Vaccine Has High Potential in Solid Tumor-Targeted Immunotherapy.
Cho SY; Jeong SM; Jeon YJ; Yang SJ; Hwang JE; Yoo BM; Kim HS
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675017
[TBL] [Abstract][Full Text] [Related]
32. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies.
Elisseeva OA; Oka Y; Tsuboi A; Ogata K; Wu F; Kim EH; Soma T; Tamaki H; Kawakami M; Oji Y; Hosen N; Kubota T; Nakagawa M; Yamagami T; Hiraoka A; Tsukaguchi M; Udaka K; Ogawa H; Kishimoto T; Nomura T; Sugiyama H
Blood; 2002 May; 99(9):3272-9. PubMed ID: 11964293
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.
Ohno S; Okuyama R; Aruga A; Sugiyama H; Yamamoto M
Anticancer Res; 2012 Jun; 32(6):2263-9. PubMed ID: 22641661
[TBL] [Abstract][Full Text] [Related]
34. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H
Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205
[TBL] [Abstract][Full Text] [Related]
35. Cancer immunotherapy targeting WT1 protein.
Sugiyama H
Int J Hematol; 2002 Aug; 76(2):127-32. PubMed ID: 12215010
[TBL] [Abstract][Full Text] [Related]
36. [Advancement of peptide vaccines for hematologic malignancies].
Zhou WJ; He YJ; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1512-7. PubMed ID: 22169315
[TBL] [Abstract][Full Text] [Related]
37. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.
Keilholz U; Letsch A; Busse A; Asemissen AM; Bauer S; Blau IW; Hofmann WK; Uharek L; Thiel E; Scheibenbogen C
Blood; 2009 Jun; 113(26):6541-8. PubMed ID: 19389880
[TBL] [Abstract][Full Text] [Related]
38. WT1 peptide vaccination for the treatment of hematological malignancies: the present status and future direction.
Oka Y; Tsuboi A; Shirakata T; Hosen N; Nishida S; Oji Y; Sugiyama H
Rinsho Ketsueki; 2009 May; 50(5):352-7. PubMed ID: 19483394
[No Abstract] [Full Text] [Related]
39. "Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further development.
Oka Y; Tsuboi A; Fujiki F; Shirakata T; Nishida S; Hosen N; Nakajima H; Li Z; Kawase I; Oji Y; Sugiyama H
Curr Med Chem; 2008; 15(29):3052-61. PubMed ID: 19075652
[TBL] [Abstract][Full Text] [Related]
40. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.
Yokota C; Kagawa N; Takano K; Chiba Y; Kinoshita M; Kijima N; Oji Y; Oka Y; Sugiyama H; Tsuboi A; Izumoto S; Kishima H; Hashimoto N
Cancer Immunol Immunother; 2022 Jan; 71(1):189-201. PubMed ID: 34089373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]